Limits...
Bioavailability Study of an Innovative Orobuccal Formulation of Glutathione.

Buonocore D, Grosini M, Giardina S, Michelotti A, Carrabetta M, Seneci A, Verri M, Dossena M, Marzatico F - Oxid Med Cell Longev (2015)

Bottom Line: When circulating GSH decreases, oral administration might be considered a therapeutic benefit.In addition, in vivo results, obtained from 15 healthy volunteers, were in favor of GSH level improvement in blood showing fast (after 30 and 60 minutes) absorption through oral mucosa.In conclusion, the intake of GSH formulated through optimized orobuccal fast-slow release tablets gave positive results in raising GSH blood concentration.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Pharmacobiochemistry, Nutrition and Nutraceuticals, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy.

ABSTRACT
Alteration of the ubiquitous thiol tripeptide glutathione (GSH) is involved in oxidative stress, which plays a role in ageing; consequently, GSH is closely related to this process characterized by progressive decline in the efficiency of physiological function and increased susceptibility to disease. When circulating GSH decreases, oral administration might be considered a therapeutic benefit. Unfortunately, due to the hydrolysis of the tripeptide by intestinal γ-glutamyltransferase, dietary glutathione is not a major determinant for its increase. Aim of this work was to evaluate improvement of GSH systemic availability testing, in vitro and in vivo, an optimized orobuccal fast-slow release formulation tablet containing pure stabilized GSH. In vitro evaluation of the penetration capability of the innovative GSH-release formulation showed that GSH was well absorbed by the reconstructed oral epithelium and its absorption has features of time-dependence. In addition, in vivo results, obtained from 15 healthy volunteers, were in favor of GSH level improvement in blood showing fast (after 30 and 60 minutes) absorption through oral mucosa. In conclusion, the intake of GSH formulated through optimized orobuccal fast-slow release tablets gave positive results in raising GSH blood concentration.

No MeSH data available.


In vitro data obtained from GSH dosage as mg in the experimental model are reported. The measured glutathione amounts are expressed as mg (mean ± standard deviation SD) in the collected medium at different experimental times and in homogenized tissue at the end of experimental period. Total absorption at the end of the experimental period is also reported considering GSH amounts in the medium at different times and in the tissue.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4663342&req=5

fig1: In vitro data obtained from GSH dosage as mg in the experimental model are reported. The measured glutathione amounts are expressed as mg (mean ± standard deviation SD) in the collected medium at different experimental times and in homogenized tissue at the end of experimental period. Total absorption at the end of the experimental period is also reported considering GSH amounts in the medium at different times and in the tissue.

Mentions: We evaluated the dose of the reduced glutathione absorbed and released by the tissue into the underlying medium following a chronological order of experimental times (10, 20, and 30 minutes) and starting with applying 0.125 mg of GSH onto units of tissue. At the end of the experimental period, we also evaluated the amount of glutathione absorbed in the tissue structure that was not released (Table 2, Figure 1).


Bioavailability Study of an Innovative Orobuccal Formulation of Glutathione.

Buonocore D, Grosini M, Giardina S, Michelotti A, Carrabetta M, Seneci A, Verri M, Dossena M, Marzatico F - Oxid Med Cell Longev (2015)

In vitro data obtained from GSH dosage as mg in the experimental model are reported. The measured glutathione amounts are expressed as mg (mean ± standard deviation SD) in the collected medium at different experimental times and in homogenized tissue at the end of experimental period. Total absorption at the end of the experimental period is also reported considering GSH amounts in the medium at different times and in the tissue.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4663342&req=5

fig1: In vitro data obtained from GSH dosage as mg in the experimental model are reported. The measured glutathione amounts are expressed as mg (mean ± standard deviation SD) in the collected medium at different experimental times and in homogenized tissue at the end of experimental period. Total absorption at the end of the experimental period is also reported considering GSH amounts in the medium at different times and in the tissue.
Mentions: We evaluated the dose of the reduced glutathione absorbed and released by the tissue into the underlying medium following a chronological order of experimental times (10, 20, and 30 minutes) and starting with applying 0.125 mg of GSH onto units of tissue. At the end of the experimental period, we also evaluated the amount of glutathione absorbed in the tissue structure that was not released (Table 2, Figure 1).

Bottom Line: When circulating GSH decreases, oral administration might be considered a therapeutic benefit.In addition, in vivo results, obtained from 15 healthy volunteers, were in favor of GSH level improvement in blood showing fast (after 30 and 60 minutes) absorption through oral mucosa.In conclusion, the intake of GSH formulated through optimized orobuccal fast-slow release tablets gave positive results in raising GSH blood concentration.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Pharmacobiochemistry, Nutrition and Nutraceuticals, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy.

ABSTRACT
Alteration of the ubiquitous thiol tripeptide glutathione (GSH) is involved in oxidative stress, which plays a role in ageing; consequently, GSH is closely related to this process characterized by progressive decline in the efficiency of physiological function and increased susceptibility to disease. When circulating GSH decreases, oral administration might be considered a therapeutic benefit. Unfortunately, due to the hydrolysis of the tripeptide by intestinal γ-glutamyltransferase, dietary glutathione is not a major determinant for its increase. Aim of this work was to evaluate improvement of GSH systemic availability testing, in vitro and in vivo, an optimized orobuccal fast-slow release formulation tablet containing pure stabilized GSH. In vitro evaluation of the penetration capability of the innovative GSH-release formulation showed that GSH was well absorbed by the reconstructed oral epithelium and its absorption has features of time-dependence. In addition, in vivo results, obtained from 15 healthy volunteers, were in favor of GSH level improvement in blood showing fast (after 30 and 60 minutes) absorption through oral mucosa. In conclusion, the intake of GSH formulated through optimized orobuccal fast-slow release tablets gave positive results in raising GSH blood concentration.

No MeSH data available.